Patents by Inventor Jhuma BHADRA

Jhuma BHADRA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligo-guanidines based cellular transporter comprising heterocyclic rings with hydrophobic and/or lipophilic groups at N-terminal for effective delivery of nonpenetrable cargos in-vitro and in-vivo
    Patent number: 10919857
    Abstract: An oligo-guanidine as cell penetrating agents/carriers includes a heterocyclic ring including 4-aminopiperidine, piperazine, morpholine having at least one N-terminal based heterocyclic ring or at least one O-heteroatom based heterocyclic ring tailored with hydrophobic and/or lipophilic group. The oligo-guanidine is adapted as an effective molecular transporter to transport and/or delivery therapeutics, therapeutic candidates, probes, or other molecules of interest across biological barriers including oligonucleotides. Advantageously, the oligo-guanidine is capable of being internalized into cells (in-vitro and in-vivo) with enhanced cellular uptake in nanomolar concentration.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 16, 2021
    Assignee: INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE
    Inventors: Surajit Sinha, Jhuma Bhadra, Sankha Pattanayak, Jayanta Kundu
  • OLIGO-GUANIDINES BASED CELLULAR TRANSPORTER COMPRISING HETEROCYCLIC RINGS WITH HYDROPHOBIC AND/OR LIPOPHILIC GROUPS AT N-TERMINAL FOR EFFECTIVE DELIVERY OF NONPENETRABLE CARGOS IN-VITRO AND IN-VIVO
    Publication number: 20190002408
    Abstract: An oligo-guanidine as cell penetrating agents/carriers includes a heterocyclic ring including 4-aminopiperidine, piperazine, morpholine having at least one N-terminal based heterocyclic ring or at least one O-heteroatom based heterocyclic ring tailored with hydrophobic and/or lipophilic group. The oligo-guanidine is adapted as an effective molecular transporter to transport and/or delivery therapeutics, therapeutic candidates, probes, or other molecules of interest across biological barriers including oligonucleotides. Advantageously, the oligo-guanidine is capable of being internalized into cells (in-vitro and in-vivo) with enhanced cellular uptake in nanomolar concentration.
    Type: Application
    Filed: June 10, 2016
    Publication date: January 3, 2019
    Inventors: Surajit SINHA, Jhuma BHADRA, Sankha PATTANAYAK, Jayanta KUNDU